Ikonisys S.A. (ALIKO.PA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 1 | 0 | 1 | - | 1 | - |
| Operating profit | €m | -3 | -4 | ||||||
| Net profit | €m | -2 | -1 | -2 | -2 | -3 | - | -4 | - |
| EPS reported | € | -0.29 | -0.27 | ||||||
| Operating cashflow per share | € | -0.12 | 0.00 | ||||||
| Capex per share | € | 0.00 | 0.00 | ||||||
| FCF per share | € | -0.12 | 0.00 | ||||||
| Free cash flow | €m | -1 | 0 | ||||||
| Net debt | €m | 4 | 2 | ||||||
| Book value equity | €m | 14 | 19 | ||||||
| Book value per share | € | 1.27 | 1.21 | ||||||
| Number of shares | m | 11.21 | 15.83 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.17 | 1.16 | ||||||
| P/S LTM | x | 16.52 | 16.02 | ||||||
| P/FCF LTM | x | -12.23 | 0.00 | ||||||
| EV/EBITDA LTM | x | -12.27 | -19.26 | ||||||
| EV/Sales LTM | x | 20.59 | 17.53 | ||||||
| Earnings Yield LTM | % | -19.39% | -18.97% | ||||||
| FCF Yield | % | -8.18% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | -22.74% | -22.03% | ||||||
| ROIC | % | -11.99% | -17.76% | ||||||
| Operating margin | % | -3.02% | -2.91% | ||||||
| Gross margin | % | +70.75% | -1.34% | ||||||
| FCF/Sales | % | -135.14% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +125.41% | +37.28% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.33 | 0.00 | ||||||
| Net Debt/EBITDA | x | -2.42 | -1.75 | ||||||
| EBIT/Net interest | x | -16.37 | -13.28 | ||||||
| Net debt/market cap | % | +30.21% | +12.14% | ||||||
| Net debt/Equity | x | 0.28 | 0.09 | ||||||
| Gross debt/equity | x | 0.29 | 0.17 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free